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Dear Editor,
With interest we read the recent
observational cohort study by
Royakkers et al. [1] that shows that
higher levels of cystatin C do not
predict the development of acute
kidney injury (AKI) nor the need for
renal replacement therapy (RRT).
Apart from the hypothesis that cyst-
atin C could detect AKI 1 or 2 days
earlier than serum creatinine, which
was not conﬁrmed in the study by
Royakkers, it is also thought that
serum cystatin C is less inﬂuenced by
RRT than creatinine, and thus better
reﬂects residual glomerular ﬁltration
rate (GFR). Determining residual
GFR is difﬁcult to establish in the
critically ill patient with no steady
state in renal function and large
changes in ﬂuid balance.
As creatinine is a small-sized mol-
ecule that is eliminated from the blood
during RRT, it is not useful for esti-
mating the residual GFR. CystatinC is
a medium-sized molecule (13.3 kDa).
Calculated from measurements in the
efferent and afferent line and from the
ultraﬁltrate line, it has been shown
that the removal of cystatin C by
continuous venovenous hemoﬁltration
(CVVH) is less than 30% of its gen-
eration and is therefore thought not to
inﬂuence serum cystatin C signiﬁ-
cantly. Although the reduction ratio
of cystatin C is dependent on the type
of membrane, dialysis dose, volume,
and ultraﬁltration rate, it is advocated
that cystatin C can be used to estimate
the residual GFR in patients on RRT
[2]. Importantly, changes in serum
cystatin C were not determined in this
study.
We determined serum creatinine
and cystatin C in 6 patients with
septic shock with AKI 48 and 24 h
prior and following the initiation of
CVVH. CVVH was performed using
the Prismaﬂex (Gambro) system with
an AN100 ST ﬁlter (polyacryloni-
trile), a blood ﬂow of 200 ml/min,
and a predilution substitution ﬂow of
2,000 ml/h. CVVH was started
according to the criteria for initiation
of RRT that were standardized by the
Acute Dialysis Quality Initiative
(ADQI) consensus [3].
We compared the serum creatinine
and cystatin C at initiation and after
24 h of CVVH with a paired
Student’s t test. We observed that
serum cystatin C decreased signiﬁ-
cantly following initiation of CVVH
(p = 0.04), whereas the decrease of
serum creatinine within the ﬁrst 24 h
was not signiﬁcant (ns, p = 0.66),
as shown in Fig. 1.
This observation was previously
described in patients that received
intermittent hemodialysis; a higher
dose of dialysis resulted in a
decreased level of serum cystatin C,
indicating that dialysis removes cyst-
atin C from the patient [4]. In a
previous study, 3 h of intermittent
hemodialysis using a polymethyl-
methacrylate ﬁlter decreased cystatin
C concentrations by 30 ± 7% [5].
This supports the hypothesis that in
different types of renal replacement
therapy serum cystatin C concentra-
tions are reduced.
In addition to the inability of
cystatin C to predict AKI better or
earlier than serum creatinine, our
ﬁnding highlights the limited value of
cystatin C in assessing residual GFR
in patients with sepsis-induced AKI.
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